Skip to main content
Premium Trial:

Request an Annual Quote

BioForce Completes $6M Private Placement

NEW YORK, March 21 (GenomeWeb) - BioForce Nanosciences said today it has closed a $6-million private placement of restricted common shares at $1.50 per share.


The financing will be used to help commercialize the NanoArrayer and for "continued development of the company's pipeline technologies," said Eric Henderson, BioForce founder and CEO, in a statement.


As GenomeWeb News reported, BioForce completed a $1.5 million bridge financing round to launch the NanoArrayer in December 2004.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.